You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 250 No. 21, December 2, 1983 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL INVESTIGATION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Chronic Myelogenous Leukemia

Development of Blast Crisis With Both Lymphoid and Myeloid Features

Keith M. Skubitz, MD; Philip R. Craddock, MB, BS, FRACP; Daniel J. Weisdorf, MD; James E. Niedel, MD, PhD; Tucker W. LeBien, PhD; John H. Kersey, MD; Richard D. Brunning, MD; Janet L. Parkin; Patrick J. Flynn, MD; Dale E. Hammerschmidt, MD

JAMA. 1983;250(21):2957-2960.


Abstract

A 50-year-old man had chronic myelogenous leukemia and entered a blast crisis that was both morphologically and histochemically lymphoid. The blasts contained terminal deoxyribonucleotidyl transferase and expressed lymphoblastic leukemia-associated antigen. He rapidly entered remission with vincristine sulfate and prednisone therapy. Nevertheless, his blasts displayed a marker generally considered unique to myeloid cells: they selectively bound the granulocyte chemotaxin N-formyl-Met-Leu-Phe. In addition, some cells contained granules resembling those of basophils or mast cells. Such mixed myeloid-lymphoid features in chronic myelogenous leukemia blast cells may reflect malignant transformation of a stem cell capable of both myeloid and lymphoid differentiation, or they may reflect the dedifferentiation as a feature of malignant change.

(JAMA 1983;250:2957-2960)



Author Affiliations

From the Departments of Medicine (Drs Skubitz, Craddock, Weisdorf, Flynn, and Hammerschmidt) and Laboratory Medicine and Pathology (Drs LeBien, Kersey, and Brunning and Ms Parkin), University of Minnesota Medical School, Minneapolis; and the Department of Medicine, Duke University Medical School, Durham, NC (Dr Niedel). Dr Craddock is now with the Department of Medicine, University of Kentucky, Lexington.


Footnotes

Reprint requests to Section of Medical Oncology, University of Minnesota School of Medicine, Box 286, Mayo Memorial Building, 420 Delaware St SE, Minneapolis, MN 55455 (Dr Skubitz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.